{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:21:34Z","timestamp":1790878894222,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders (renal osteodystrophy), myopathy, neurologic abnormalities, anemia, pruritus, and cardiomyopathy. Hyperparathyroidism is common in CKD and results in significant morbidity and mortality if left untreated. Clinical practice guidelines from the Kidney Disease Improving Global Outcomes initiative broadened the optimal PTH range to &gt;2 and &lt;9 times the upper limit of normal for the assay measured. Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy. These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients. They also require frequent measurement in order to determine trends and implement appropriate treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.04650512","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T23:06:12Z","timestamp":1349391972000},"page":"313-318","source":"Crossref","is-referenced-by-count":31,"title":["The Case for Routine Parathyroid Hormone Monitoring"],"prefix":"10.2215","volume":"8","author":[{"given":"Stuart M.","family":"Sprague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20-20230811","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI106517","article-title":"On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.","volume":"50","author":"Slatopolsky","year":"1971","journal-title":"J Clin Invest"},{"key":"R3-20-20230811","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJM197205182862009","article-title":"On the pathogenesis of the uremic state. An exposition of the \u201ctrade-off hypothesis\u201d.","volume":"286","author":"Bricker","year":"1972","journal-title":"N Engl J Med"},{"key":"R5-20-20230811","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/qjmed\/77.2.1175","article-title":"Parathyroidectomy in chronic renal failure: A nine-year follow-up study.","volume":"77","author":"Nichols","year":"1990","journal-title":"Q J Med"},{"key":"R6-20-20230811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(196901)23:1<1::AID-CNCR2820230101>3.0.CO;2-W","article-title":"Granulomatous thymoma or Hodgkin\u2019s disease of thymus? A clinical and histologic study and a re-evaluation.","volume":"23","author":"Katz","year":"1969","journal-title":"Cancer"},{"key":"R7-20-20230811","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0272-6386(03)00909-0","article-title":"Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism.","volume":"42","author":"Yajima","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R8-20-20230811","first-page":"172","article-title":"Response to parathyroidectomy at the axial and appendicular skeleton in renal patients.","volume":"52","author":"Stein","year":"1999","journal-title":"Clin Nephrol"},{"key":"R9-20-20230811","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","article-title":"Fracture risk after parathyroidectomy among chronic hemodialysis patients.","volume":"18","author":"Rudser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R10-20-20230811","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","article-title":"Survival following parathyroidectomy among United States dialysis patients.","volume":"66","author":"Kestenbaum","year":"2004","journal-title":"Kidney Int"},{"key":"R11-20-20230811","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","article-title":"Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.","volume":"321","author":"Andress","year":"1989","journal-title":"N Engl J Med"},{"key":"R12-20-20230811","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM199008093230617","article-title":"Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis.","volume":"323","author":"Fukagawa","year":"1990","journal-title":"N Engl J Med"},{"key":"R13-20-20230811","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"R14-20-20230811","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1523-1755.1998.00782.x","article-title":"NPS R-568 halts or reverses osteitis fibrosa in uremic rats.","volume":"53","author":"Wada","year":"1998","journal-title":"Kidney Int"},{"key":"R15-20-20230811","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/ndt\/gfp078","article-title":"R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).","volume":"24","author":"Moe","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R16-20-20230811","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1744-9987.2008.00630.x","article-title":"Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.","volume":"12","author":"Yajima","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R18-20-20230811","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1203\/00006450-197312000-00006","article-title":"A review: Short stature in renal disease.","volume":"7","author":"Stickler","year":"1973","journal-title":"Pediatr Res"},{"key":"R19-20-20230811","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/adc.50.7.545","article-title":"Slipped epiphyses in renal osteodystrophy.","volume":"50","author":"Mehls","year":"1975","journal-title":"Arch Dis Child"},{"key":"R20-20-20230811","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ki.1973.91","article-title":"Some biochemical, histological, radiological and clinical features of renal osteodystrophy.","volume":"4","author":"Eastwood","year":"1973","journal-title":"Kidney Int"},{"key":"R21-20-20230811","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archneur.1980.00500580051007","article-title":"Proximal muscle weakness in uremia. Case reports and review of the literature.","volume":"37","author":"Lazaro","year":"1980","journal-title":"Arch Neurol"},{"key":"R22-20-20230811","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000181394","article-title":"Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure.","volume":"21","author":"Lotem","year":"1978","journal-title":"Nephron"},{"key":"R23-20-20230811","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/039139880102401004","article-title":"Uremic toxicity: Present state of the art.","volume":"24","author":"Vanholder","year":"2001","journal-title":"Int J Artif Organs"},{"key":"R24-20-20230811","first-page":"219","article-title":"Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia.","volume":"14","author":"Massry","year":"1994","journal-title":"Semin Nephrol"},{"key":"R25-20-20230811","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI110137","article-title":"Effect of parathyroid hormone on rat heart cells.","volume":"67","author":"Bogin","year":"1981","journal-title":"J Clin Invest"},{"key":"R26-20-20230811","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1172\/JCI107984","article-title":"Changes in the electroencephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes.","volume":"55","author":"Guisado","year":"1975","journal-title":"J Clin Invest"},{"key":"R27-20-20230811","first-page":"F575","article-title":"Role of uremia, brain calcium, and parathyroid hormone on changes in electroencephalogram in chronic renal failure.","volume":"246","author":"Akmal","year":"1984","journal-title":"Am J Physiol"},{"key":"R28-20-20230811","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ki.1995.18","article-title":"Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy.","volume":"47","author":"Akmal","year":"1995","journal-title":"Kidney Int"},{"key":"R29-20-20230811","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/jcem-51-1-130","article-title":"The relationship between the abnormalities in electroencephalogram and blood levels of parathyroid hormone in dialysis patients.","volume":"51","author":"Goldstein","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20-20230811","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0002-9343(78)90748-9","article-title":"Central nervous system manifestations of hyperparathyroidism.","volume":"65","author":"Cogan","year":"1978","journal-title":"Am J Med"},{"key":"R31-20-20230811","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM197805042981805","article-title":"Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.","volume":"298","author":"Avram","year":"1978","journal-title":"N Engl J Med"},{"key":"R32-20-20230811","first-page":"59","article-title":"Uremic syndrome in man: New evidence for parathormone as a multisystem neurotoxin.","volume":"11","author":"Avram","year":"1979","journal-title":"Clin Nephrol"},{"key":"R33-20-20230811","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM199301213280304","article-title":"Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.","volume":"328","author":"Rao","year":"1993","journal-title":"N Engl J Med"},{"key":"R34-20-20230811","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1172\/JCI110154","article-title":"Effect of parathyroid hormone on erythropoiesis.","volume":"67","author":"Meytes","year":"1981","journal-title":"J Clin Invest"},{"key":"R35-20-20230811","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000186596","article-title":"Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomy.","volume":"59","author":"Ure\u00f1a","year":"1991","journal-title":"Nephron"},{"key":"R36-20-20230811","first-page":"203","article-title":"The disappearance of intractable pruritus after parathyroidectomy in uremic patients with secondary hyperparathyroidism.","volume":"81","author":"Kleeman","year":"1968","journal-title":"Trans Assoc Am Physicians"},{"key":"R37-20-20230811","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0272-6386(96)90519-3","article-title":"Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation.","volume":"27","author":"Goldsmith","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"R38-20-20230811","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(80)90602-9","article-title":"Effect of parathyroidectomy on left-ventricular function in haemodialysis patients.","volume":"1","author":"Dr\u00fceke","year":"1980","journal-title":"Lancet"},{"key":"R39-20-20230811","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0272-6386(12)80090-4","article-title":"Parathyroid hormone and myocardial performance in dialysis patients.","volume":"18","author":"Fellner","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"R40-20-20230811","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R41-20-20230811","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R42-20-20230811","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0272-6386(99)70260-X","article-title":"Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.","volume":"33","author":"Park","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R43-20-20230811","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial.","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"R44-20-20230811","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R45-20-20230811","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.ki.5002241","article-title":"Vascular calcification: Contribution of parathyroid hormone in renal failure.","volume":"71","author":"Neves","year":"2007","journal-title":"Kidney Int"},{"key":"R46-20-20230811","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem.82.1.3666","article-title":"Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up.","volume":"82","author":"Stefenelli","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R47-20-20230811","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archinte.1976.03630110043012","article-title":"Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure.","volume":"136","author":"Gipstein","year":"1976","journal-title":"Arch Intern Med"},{"key":"R48-20-20230811","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1525-139X.2007.00263.x","article-title":"Calcific uremic arteriolopathy: Advances in pathogenesis and treatment.","volume":"20","author":"Rogers","year":"2007","journal-title":"Semin Dial"},{"key":"R49-20-20230811","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5414\/CNP72005","article-title":"The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients.","volume":"72","author":"Herberth","year":"2009","journal-title":"Clin Nephrol"},{"key":"R50-20-20230811","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.clinbiochem.2007.03.019","article-title":"Update on parathyroid hormone: New tests and new challenges for external quality assessment.","volume":"40","author":"Cole","year":"2007","journal-title":"Clin Biochem"},{"key":"R51-20-20230811","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.2001.16.4.605","article-title":"Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function.","volume":"16","author":"Gao","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R52-20-20230811","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1744-9987.2011.00926.x","article-title":"Comparison between whole and intact parathyroid hormone assays.","volume":"15","author":"Taniguchi","year":"2011","journal-title":"Ther Apher Dial"},{"key":"R54-20-20230811","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2215\/CJN.09471209","article-title":"Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.","volume":"5","author":"Gardham","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R55-20-20230811","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/acb.2011.011094","article-title":"Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease.","volume":"49","author":"Almond","year":"2012","journal-title":"Ann Clin Biochem"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201302000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:38Z","timestamp":1786369358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201302000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04650512","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}